

Patient-specific aorta-on-a-chip models for thoracic aortic aneurysm and dissection

Created on: 11-06-2024 - Last modified on: 06-08-2025

Contact person

Ivanna Fedoryshchenko

Organisation

Name of the organisation University of Antwerp (UAntwerpen)

Department Center of Medical Genetics

Country Belgium

Geographical Area Flemish Region

SCOPE OF THE METHOD

The Method relates to	Human health
The Method is situated in	Basic Research, Translational - Applied Research
Type of method	In vitro - Ex vivo
Specify the type of cells/tissues/organs	Endothelial and vascular smooth muscle cells derived from iPSCs, generated from PBMCs or fibroblasts

DESCRIPTION

Method keywords

Aorta-on-a-chip

Microfluidic device

blood vessel

Human induced Pluripotent Stem Cell

Scientific area keywords

Cardiogenetics

thoracic aortic aneurysm

vascular biology

Induced pluripotent stem cells

Method description

Thoracic aortic aneurysm (TAA) involves the progressive enlargement of the thoracic aorta, posing a significant risk for life-threatening aortic dissection and/or rupture. Currently, mouse models are frequently used to investigate and target the molecular defects underlying TAA, due to the difficulty in collecting native aortic samples from patients and especially control individuals. However, murine *in vivo* studies are often lengthy, and drug testing results have not always translated to patient outcomes. The existing vascular smooth muscle cell (VSMC) or endothelial cell (EC) monocultures are simplified and fail to replicate the complex multilayered and multicellular structure of the aorta adequately. To address this, we aim to develop and validate the first iPSC-derived TAA aorta-on-a-chip models using induced pluripotent stem cells (iPSCs). PDMS chips will be seeded with the key cell types found in the ascending aorta, with pressure and shear stress applied to mimic the native environmental conditions. Once the patient model is established, we will demonstrate its ability to recapitulate established cellular and molecular disease processes and drug responses.

Method status

Still in development

PROS, CONS & FUTURE POTENTIAL

Advantages

- Using patient-derived iPSCs provides complete genetic background and allows a more accurate representation of human disease mechanisms,
- By including key cell types and mimicking the complex structure of the aorta, the model will offer more comprehensive insights into disease mechanisms and drug responses,
- Applying pressure and shear stress to the chips replicates the native physiological conditions, enhancing the model's accuracy in simulating the disease environment.

Challenges

- There can be significant variability between iPSC lines, which may affect the reproducibility and consistency of the model,
- While the model aims to replicate the aortic environment, it may still lack some nuances of the *in vivo* conditions, such as interactions with other cell types, and hormones,
- The long-term stability and functionality of the model is yet to be established.

Modifications

Introduce other relevant cell types such as fibroblasts, immune cells (e.g., macrophages), and pericytes to more closely mimic the cellular diversity of the native aorta.

Future & Other applications

- Study other types of aneurysms, such as abdominal aortic aneurysms.
- Study the effects of high blood pressure on the aorta and its cellular components.
- Assess the cardiovascular toxicity of new drug candidates, reducing the risk of adverse effects.
- Use the model to predict how individual patients might respond to specific drugs, enhancing personalized treatment plans.

REFERENCES, ASSOCIATED DOCUMENTS AND OTHER INFORMATION

Coordinated by









